Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating Activities:
Net loss	$ (9,354)	$ (46,575)
Adjustments to reconcile net loss to net cash provided by operating activities:
Loss on right of use assets	0	143
Depreciation and amortization	7,627	6,029
Amortization-investment discount	(370)	(1,153)
Amortization-debt issuance costs	440	520
Equity-based compensation	17,187	20,854
Non-cash lease expense	395	472
Changes in operating assets and liabilities:
Accounts receivable	(60,155)	(45,322)
Prepaid expenses and other current assets	(43,800)	(8,886)
Other assets	(23)	(114)
Medical expenses payable	106,946	71,065
Accounts payable and accrued expenses	5,208	48
Deferred premium revenue	157	(59)
Accrued compensation	(7,577)	(2,505)
Lease liabilities	(65)	(755)
Net cash provided by (used in) operating activities	16,616	(6,238)
Investing Activities:
Purchase of investments	(17,905)	(21,564)
Maturities of investments	22,695	75,390
Acquisition of property and equipment	(8,252)	(11,121)
Net cash (used in) provided by investing activities	(3,462)	42,705
Financing Activities:
Payment of employment taxes related to release of restricted stock	0	(350)
Debt issuance costs	(26)	0
Proceeds from stock option exercises	207	0
Contributions from noncontrolling interest holders	0	15
Net cash provided by (used in) financing activities	181	(335)
Net increase in cash	13,335	36,132
Cash, cash equivalents and restricted cash at beginning of period	434,942	204,954
Cash, cash equivalents and restricted cash at end of period	448,277	241,086
Supplemental disclosure of cash flow information:
Cash paid for interest	0	5,175
Supplemental non-cash investing and financing activities:
Acquisition of property in accounts payable	85	156
Reconciliation of cash, cash equivalents and restricted cash as shown in the statement of cash flows:
Cash and cash equivalents	446,184	238,903
Restricted cash in other assets	2,093	2,183
Total	$ 448,277	$ 241,086